Literature DB >> 33621148

Contemporaneous Risk Factors for Visual Acuity in Non-Infectious Uveitis.

Maxwell Pistilli1, Sapna S Gangaputra2, Siddharth S Pujari3, Douglas A Jabs4,5, Grace A Levy-Clarke6,7, Robert B Nussenblatt6, James T Rosenbaum8,9, H Nida Sen6, Eric B Suhler8,9,10, Jennifer E Thorne4,5, Nirali P Bhatt1, C Stephen Foster11,12, Hosne Begum5, Tonetta D Fitzgerald1, Kurt A Dreger1,5, John H Kempen12,13,14.   

Abstract

INTRODUCTION: We evaluated the associations of clinical and demographic characteristics with visual acuity (VA) with over 5 years in a subspecialty noninfectious uveitis population.
METHODS: Retrospective data from 5,530 noninfectious uveitis patients were abstracted by expert reviewers, and contemporaneous associations of VA with demographic and clinical factors were modeled.
RESULTS: Patients were a median of 41 years old, 65% female, and 73% white. Eyes diagnosed ≥5 years prior to cohort entry had worse VA (-1.2 lines) than those diagnosed <6 months prior, and eyes with cataract surgery performed prior to entry had worse VA (-5.9 lines) than those performed during follow-up. Vitreous haze (-4.2 lines for 3+ vs quiet), hypotony (-2.5 lines for ≤5 mm Hg vs 6-23 mm Hg), and CNV (-1.8 lines) all were strongly associated with reduced VA.
CONCLUSION: Factors associated with reduced VA included well-known structural complications, and lack of subspecialty care during cataract surgery.

Entities:  

Keywords:  Visual Acuity; risk Factors; uveitis

Mesh:

Year:  2021        PMID: 33621148     DOI: 10.1080/09273948.2020.1828493

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  1 in total

1.  Risk of Cataract in Intermediate Uveitis.

Authors:  Caroline L Minkus; Maxwell Pistilli; Kurt A Dreger; Tonetta D Fitzgerald; Abhishek R Payal; Hosne Begum; R Oktay Kaçmaz; Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum; Grace A Levy-Clarke; H Nida Sen; Eric B Suhler; Jennifer E Thorne; Nirali P Bhatt; C Stephen Foster; Jeanine M Buchanich; John H Kempen
Journal:  Am J Ophthalmol       Date:  2021-03-10       Impact factor: 5.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.